Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2025 Earnings Presentation
17 slides from Alkem Laboratories's earnings presentation, May 29, 2025
Slide 1: Investor Presentation Q4 & FY25
Investor Presentation Q4 & FY25 May 29, 2025
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q4FY25
KEY HIGHLIGHTS OF Q4FY25 • Total Revenue from Operations were ₹ 31,438 million, year-on-year growth of 7.1%. • India sales were ₹ 21,355 million, year-on-year growth of 8.1%. • The contribution of domestic sales to total sales in Q4FY25 was 68.7% vs. 68.5% in Q4FY24. • International sales were ₹ 9,7
Slide 4: Key Financial Highlights – Q4FY25 (Consolidated)
KEY FINANCIAL HIGHLIGHTS – Q4FY25 (CONSOLIDATED) All figures in ₹ Mn Revenue from Operations India sales 21,355 19,755 31,438 29,358 Q4FY24 Q4FY25 International sales 9,747 9,096 Q4FY24 Q4FY25 Q4FY24 Q4FY25
Slide 5: Key Financial Highlights – Q4FY25 (Consolidated)
KEY FINANCIAL HIGHLIGHTS – Q4FY25 (CONSOLIDATED) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin PBT (before exceptional item) 18,284 18,645 3,799 3,963 4,020 3,913 62.3% 59.3% 13.7% 12.4% Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 PBT (after exceptional item) PAT (after Mi
Slide 6: India - Secondary Sales Performance (Q4FY25)
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in Q4FY25 1 3 3 2 9 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 14.1% 13.1% 9.6% 10.0% 7.2% 5.6% 2.3% 3.3% 4.1% 2.6% Alkem sales growth
Slide 7: India Business Update
INDIA BUSINESS UPDATE Q4FY25 Sales of ₹ 21,355 million (8.1% YoY growth) • Contribution of domestic sales to total sales in Q4FY25 was 68.7% and for FY25 was 70.2%. • We outperformed the IPM growth in GI, Gynaec, Respiratory and VMN therapies, and our ranking improved in therapies like Anti- diabeti
Slide 8: US Business Update
US BUSINESS UPDATE Q4FY25 Sales of ₹ 6,086 million (2.5% YoY de-growth) • Overall contribution of US sales to total sales was 19.6% in Q4FY25 and 19.4% in FY25. • During Q4FY25, the US business de-grew by 2.5% and in FY25 it de-grew by 10.4%. • During Q4FY25, the Company has filed 6 ANDAs and has re
Slide 9: Update on USFDA Inspections
UPDATE ON USFDA INSPECTIONS Facility Capability Inspection Date Regulatory Status Baddi (India) Formulations Mar-24 EIR Received in June 2024 Daman (India) Formulations Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Bioequivalence Centre Mar-25 No observation Ankleshwar (India) API Apr-23 EIR Re
Slide 10: Other International Business Update
OTHER INTERNATIONAL BUSINESS UPDATE Q4FY25 Sales of ₹ 3,661 million (28.2% YoY growth) • Other International Market sales contributed 11.8% to total sales in Q4FY25 and 10.5% in FY25. • The Non-US business demonstrated solid performance, growing by around 28.2% YoY, fuelled by robust double-digit gr
Slide 11: Key Highlights of FY25
KEY HIGHLIGHTS OF FY25 • Total Revenue from Operations was ₹ 129,645 million, year-on-year growth of 2.3%. • India sales were ₹ 89,837 million, year-on-year growth of 6.5%. • The contribution of domestic sales to total sales in FY25 was 70.2% vs. 67.8% in FY24. • International sales were ₹ 38,210 mi
Slide 12: Key Financial Highlights - FY25 (Consolidated)
KEY FINANCIAL HIGHLIGHTS - FY25 (CONSOLIDATED) All figures in ₹ Mn Revenue from Operations India sales 89,837 84,368 126,676 129,645 FY24 FY25 International sales 40,024 38,210 FY24 FY25 FY24 FY25
Slide 13: Key Financial Highlights - FY25 (Consolidated)
KEY FINANCIAL HIGHLIGHTS - FY25 (CONSOLIDATED) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin PBT (before exceptional item) 25,122 25,270 77,300 82,003 22,455 21,446 61.0% 63.3% 17.7% 19.4% FY24 FY25 FY24 FY25 FY24 FY25 PBT (after exceptional item) PAT (after Minority Int
Slide 14: India - Secondary Sales Performance (FY25)
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in FY25 1 3 3 2 8 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.7% 11.4% 9.6% 7.8% 7.0% 6.8% 2.5% 4.8% 5.0% 3.3% Alkem sales growth Yo
Slide 15: Shareholding Pattern as on March 31, 2025
SHAREHOLDING PATTERN AS ON MARCH 31, 2025 BSE Ticker 539523 NSE Symbol ALKEM Non- Institution Shares Outstanding (Mn) 120 16.1% MCap (Rs in Mn)* 583,607 Promoter & Institution Promoter Group Free Float Mcap (Rs in Mn) 258,713 28.8% 55.1% Industry Pharmaceuticals *Share Price - Rs 4,882 from NSE as o
Slide 16: Key Financial Highlights – Q4FY25 & FY25 (Consolidated)
KEY FINANCIAL HIGHLIGHTS – Q4FY25 & FY25 (CONSOLIDATED) All figures in ₹ Mn Particulars Q4FY25 Q4FY24 YoY growth FY25 FY24 YoY growth Revenue from Operations 31,438 29,358 7.1% 129,645 126,676 2.3% Gross Profit 18,645 18,284 2.0% 82,003 77,300 6.1% Gross Profit Margin 59.3% 62.3% 63.3% 61.0% EBITDA
Slide 17: Thank You
THANK YOU For any queries, contact: Purvi Shah - Head of Investor Relations Mobile: +91 84337 00890 | Tel: +91 22 3982 9999 Ext: 9447 E-mail: purvi.shah@alkem.com